News Author: Andrew D. Bowser Publish date: December 12, 2018
In an analysis of SEER data, 2-year survival was 52% and 14%, respectively, for RCC patients with brain-only metastases who did and did not undergo...
News Author: Andrew D. Bowser Publish date: December 11, 2018
In a retrospective study of data on 287 metastatic RCC patients who underwent cytoreductive nephrectomy, the ratio of apolipoproteins B and A1 was ...
News Author: Andrew D. Bowser Publish date: December 10, 2018
Clinicians need to be vigilant for RCCs in melanoma patients, and for melanomas in RCC patients.
News Author: Andrew D. Bowser Publish date: December 9, 2018
SAN DIEGO—Emapalumab, an interferon gamma-blocking antibody, controls disease activity and has a favorable safety profile in pediatric patients with p...
News Author: Andrew D. Bowser Publish date: December 7, 2018
SAN DIEGO – The simple blood test costs about $2 and has an accuracy of 99%.
Video Author: Andrew D. Bowser Publish date: December 6, 2018
SAN DIEGO – The CASSINI trial evaluates VTE prophylaxis in ambulatory patients receiving systemic therapy.
News Author: Andrew D. Bowser Publish date: December 6, 2018
SAN DIEGO—Daily hydroxyurea (HU) treatment is feasible, safe, and effective for children with sickle cell disease (SCD) in sub-Saharan Africa, accordi...
Video Author: Andrew D. Bowser Publish date: December 4, 2018
SAN DIEGO – Results from the PAUSE study could set the standard for timing of perioperative DOAC interruption.
News Author: Andrew D. Bowser Publish date: December 4, 2018
An after-hours phone triage system, proactive chemotherapy follow-up calls, and a Saturday-Sunday urgent care clinic resulted in early intervention...
Video Author: Andrew D. Bowser Publish date: December 4, 2018
SAN DIEGO – Five new ASH guidelines for sickle cell disease are on the way, likely early in 2019.
News Author: Andrew D. Bowser Publish date: December 4, 2018
SAN DIEGO – There is “certainly room for enlarging the indication” to first-line treatment of HLH once a sufficient number of previously untreated ...
News Author: Andrew D. Bowser Publish date: December 4, 2018
SAN DIEGO—Ixazomib improved progression-free survival (PFS) following autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple...
News Author: Andrew D. Bowser Publish date: December 3, 2018
SAN DIEGO – A lower dose of rituximab appears effective, but it still carries side effects.
News Author: Andrew D. Bowser Publish date: December 3, 2018
SAN DIEGO—Results of the randomized, phase 3 Medalist trial show that the erythroid maturation agent luspatercept can reduce transfusion burden in pat...
News Author: Andrew D. Bowser Publish date: December 2, 2018
SAN DIEGO – A leading investigator put the results in perspective with the currently approved lenalidomide, and the audience questions as to whethe...
